What Berbrick does

Berbrick is a private pharmaceutical marketing company headquartered in Mumbai, India, founded in 2018. It markets a portfolio of 61 branded formulations across five therapeutic divisions — Gastro Care, Critical Care, Ortho Care, Respiratory Care, and Nutra Care — covering proton pump inhibitors, prokinetics, probiotics, carbapenem and beta-lactam antibiotics, NSAIDs, muscle relaxants, hepatoprotectives, antihistamines, bronchodilators, and a range of nutritional supplements and enteral nutrition products. The company's go-to-market is sales-led and executed through direct engagement with physicians, hospitals, and clinics, supplemented by a network of pharmaceutical distributors across India and an owned e-commerce storefront at berbrick.in/shop. Brand-building is reinforced by regular participation in Indian specialty medical conferences such as ISN, ESICON, WCN, and ISNSCCON.

Name

Berbrick

Legal name

Berbrick

Website

https://berbrick.in

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Berbrick is a Mumbai-based pharmaceutical marketing company founded in 2018 that sells 61 branded formulations across gastro, critical, orthopedic, respiratory, and nutritional therapeutic divisions to doctors, hospitals, and distributors across India.

Ownership category

akta.pro rank

Product category

Pharmaceutical Formulations

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

akta.pro secondary industries

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Specialty Pharmaceutical Distributors (HLAIAJAB), Pharmacy Front-End & Sundries Distribution (Health & Wellness, Personal Care, Convenience) (CRAOAHAG)

Keywords

• Pharmaceutical formulations
• Branded generic medicines
• Critical care injectables
• Nutraceutical supplements
• Enteral nutrition products

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Marketing and selling pharmaceutical formulations across five therapeutic divisions through direct sales to healthcare professionals, hospitals, clinics, and distribution partners.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Berbrick is a pharmaceutical company that markets a portfolio of 61+ branded pharmaceutical formulations across five therapeutic divisions: Gastro Care, Critical Care, Ortho Care, Respiratory Care, and Nutra Care. The offerings include prescription medicines (proton pump inhibitors, antibiotics, NSAIDs, hepatoprotectives), critical care injectables, orthopedic and bone health products, respiratory therapies, and science-backed nutraceutical and enteral nutrition supplements. Products are sold to healthcare professionals, hospitals, distributors, and via a company-owned online shop in India.

Product overview

Berbrick is a progressive pharmaceutical company headquartered in Mumbai, established in 2018, engaged in the marketing of a wide range of pharmaceutical formulations across five therapeutic divisions: Gastro Care, Critical Care, Ortho Care, Respiratory Care, and Nutra Care. The portfolio includes prescription medicines (antibiotics, proton pump inhibitors, NSAIDs, muscle relaxants, hepatoprotectives), critical care injectables (carbapenems, combination antibiotics, TPN solutions), orthopedic treatments (bone health supplements, NSAIDs, enzyme combinations), respiratory products (antihistamines, bronchodilators, respiratory antibiotics), and nutraceuticals (enteral nutrition formulas, protein supplements, vitamin D supplements, probiotics, and multi-nutrient formulations). The company operates primarily in India with a focus on quality pharmaceuticals and nutritional products.

Differentiator

Problem solved

Functional benefit

Products and services

• ESOBRICK 40 Esomeprazole 40 mg proton pump inhibitor tablet indicated for GERD and functional dyspepsia, marketed to gastroenterologists and general physicians.
• ESOBRICK-D PPI-based combination product for acid-related gastrointestinal disorders.
• ESOBRICK-L PPI with levosulpiride combination capsule for gastroesophageal reflux and motility disorders.
• ESOBRICK-IT Esomeprazole EC 40 mg with Itopride Hydrochloride SR 150 mg capsule for GERD, diabetic gastroparesis, and acid peptic disorders.
• PROBRICK Probiotic formulation with elemental zinc, Lactobacillus, and Saccharomyces Boulardii for antibiotic-associated diarrhea, IBS, and functional gut issues.
• PROBRICK PLUS Probiotic capsules with Bacillus Clausii for SIBO, IBD, and post-antibiotic recovery.
• ACOTIF Acotiamide Hydrochloride 300 mg sustained-release tablet, a first-in-class prokinetic for Postprandial Distress Syndrome in Functional Dyspepsia.
• INBERP-DSR Pantoprazole 40 mg with Domperidone 30 mg prolonged release capsule for acid reflux with delayed gastric emptying.
• MEROMIX Meropenem 1 g sterile pyrogen-free carbapenem antibiotic injection for intravenous administration against gram-positive, gram-negative, and anaerobic infections.
• PEPTIZA Piperacillin and Tazobactam injection for systemic bacterial infections including respiratory, urinary, intra-abdominal, and skin infections.
• GLOMUNE IV L-Alanyl-L-Glutamine infusion 20% sterile solution for Total Parenteral Nutrition in critically ill, ICU, severe burn, and post-surgical patients.
• ZOBRICK Cefoperazone 1 g with Sulbactam 500 mg injection for treating beta-lactamase producing resistant bacterial infections.
• FLAXMOX CV Amoxicillin with Clavulanic Acid and Lactic Acid Bacillus triple formulation antibiotic with probiotic.
• REFABER 550 Rifaximin 550 mg non-systemic broad-spectrum oral antibiotic tablet for diarrhea associated with IBD/IBS, hepatic encephalopathy, and traveler's diarrhea.
• LINZOBRICK 600MG TAB Linezolid 600 mg oxazolidinone-class antibiotic tablet for serious gram-positive bacterial infections including MRSA.
• BERCOX 90MG Etoricoxib 90 mg COX-2 selective NSAID tablet for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
• BERCOX MR Etoricoxib 60 mg with Thiocolchicoside 4 mg combination tablet combining anti-inflammatory NSAID with muscle relaxant for musculoskeletal pain.
• THIOBER P Thiocolchicoside, Aceclofenac, and Paracetamol triple combination tablet for pain, fever, and inflammation.
• BERFENAC SP Aceclofenac 100 mg with Paracetamol 325 mg and Serratiopeptidase 15 mg triple action tablet for pain, fever, edema, and musculoskeletal conditions.
• CALBRICK PRO Calcitriol with Calcium Carbonate, DHA, EPA, Boron, Folic Acid, and Methylcobalamin softgel capsule for osteopenia and osteoporosis treatment.
• BERHCQ 200MG Hydroxychloroquine 200 mg tablet for rheumatoid arthritis, polyarthritis associated with Chikungunya, and post-Chikungunya arthritis.
• ALENZA-L Montelukast 10 mg with Levocetirizine 5 mg film-coated tablet for allergic rhinitis.
• ALENZA-B Bilastine 20 mg with Montelukast Sodium 10 mg film-coated tablet for allergic conditions.
• NACMAC-AB Acebrophylline 100 mg with N-Acetylcysteine 600 mg tablet for chronic bronchopulmonary diseases, COPD, bronchial asthma, and pulmonary complications.
• ZAXIS Azithromycin 500 mg broad-spectrum macrolide antibiotic tablet for respiratory, skin, and genitourinary infections.
• B-NUTRA-1.0 (KESAR ELAICHI) Complete and balanced enteral nutrition formula with 25 g high-quality protein, 8 g dietary fiber including FOS, 447 kcal per 100 g, and 39 essential nutrients.
• B-NUTRA-2.0 (MANGO ALMOND) 100% Whey Protein calorie-dense enteral nutrition formula with 474 kcal per 100 g and 35 g protein, suitable for oral or tube feeding.
• B-NUTRA-DM (KESAR ELAICHI) Complete balanced nutrition formulation for individuals with diabetes, featuring low glycemic index, high protein, high fiber, and sucrose-free formulation.
• B-NUTRA-GOLD High-protein, high-fiber nutritional formulation with 19.05 g protein per serving, BCAAs, L-Carnitine, and vitamins for muscle support and metabolic recovery.
• B-NUTRA-BCAA Oral nutritional supplement with BCAAs (Leucine, Isoleucine, Valine) and Zinc for liver health and chronic liver disease support.
• B-NUTRA-HP High protein formulation with 63.5 g protein per 100 g and multimineral combination for immunity boost, in Kesar Elaichi flavour.
• GLOMUNE ZS Nutritional sachet with L-Glutamine, Zinc, and Selenium for immune response, tissue repair, and oxidative stress reduction in cancer, critical illness, or burn patients.
• CALBRICK D3 Sachets Cholecalciferol (Vitamin D3) 60,000 IU granules in sachets for treatment and prevention of vitamin D deficiency.
• CALBRICK D3 Sachets Cholecalciferol (Vitamin D3) 60,000 IU granules in sachets for treatment and prevention of vitamin D deficiency.

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Macleods Pharmaceuticals: Large Indian multi-therapy pharma company with strong presence in anti-infectives, gastro, respiratory and critical care. Highly comparable therapeutic footprint and contract-manufacturing/marketing orientation to Berbrick.
• Ajanta Pharma: Indian specialty pharma with branded generics across multiple therapeutic areas including gastro and respiratory. Comparable to Berbrick in product mix, though materially larger and export-heavy.
• Alkem Laboratories: Large Indian branded-generics pharma company with multi-therapy coverage (gastro, critical care, ortho, respiratory, nutraceuticals). Comparable to Berbrick because of overlapping therapeutic divisions and a similar India-focused marketing-led GTM, though at vastly greater scale.
• Mankind Pharma: India's leading domestic pharma player with broad prescription and OTC/nutraceutical portfolios across gastro, cardiac, respiratory and wellness categories. Comparable to Berbrick in therapy breadth and India-centric distribution model.
• Torrent Pharmaceuticals: Mid-to-large Indian pharma with strong gastro/hepatology and chronic-care franchises. Comparable to Berbrick in therapeutic emphasis and India-centric branded-generics GTM.
• Cipla: One of India's largest pharma companies with deep respiratory, gastro, and critical care portfolios. A broad incumbent that competes with Berbrick for the same specialist prescriber base across overlapping therapy areas.

Emerging players

• Corona Remedies: Mid-sized Indian pharma with multi-therapy branded-generics focus across gastro, ortho and women's health. Similar in scale, therapy breadth and India-domestic marketing orientation to Berbrick.
• Akums Drugs & Pharmaceuticals: India's largest contract manufacturer of pharma formulations with growing own-brand presence across gastro, ortho, and nutraceuticals. Comparable as a fellow India-based multi-therapy formulation company at a similar growth-stage profile.
• Zuventus Healthcare: India-focused branded-generics pharma (part of Emami group) with portfolio overlap in gastro, respiratory, and ortho specialties. Comparable therapeutic mix and India-domestic marketing-led model.

Direct peers

• Eris Lifesciences: India-focused specialty pharma company concentrated in chronic therapy areas (gastro, cardio-metabolic, ortho) with a similar super-specialist doctor-focused sales motion. Strongest direct comparability to Berbrick in scale, therapy mix, and channel strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/berbrick

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Berbrick